In this biography
Quick facts
- Born
- 1955
- Birthplace
- United States
- Country
- United States
- Nationality
- Not independently established
- Known for
- Helping develop and clinically investigate imatinib as a molecularly directed treatment for chronic myeloid leukaemia
Why this life matters
His work is most informative when the experimental stages and the people responsible for them remain visible.
Timeline
Key moments
Birth
Born in the United States; reviewed award sources disagree about the specific city.
Oregon research programme
Moved his research programme to Oregon.
Early clinical results
Co-authored a phase 1 report in chronic-phase CML after interferon failure.
A clinical question and a research route
Brian Druker was born in the United States in 1955 and grew up in St Paul, Minnesota. He studied at the University of California, San Diego, completing medical training before residency and research work associated with Washington University and Dana-Farber. OHSU’s career account describes a physician-scientist interested in connecting laboratory findings with a disease he encountered clinically. His move to Oregon in 1993 provided the setting for work that would become a major example of molecularly directed cancer research.
A collaboration across institutions
The Lasker Foundation’s historical account credits a group rather than a single person. Nicholas Lydon, Elisabeth Buchdunger and Jürg Zimmermann contributed to the compound-development programme, while Druker’s laboratory helped connect it with BCR-ABL-positive cells and a clinical question. The 1996 paper’s author list and affiliations make that cross-institutional work visible. Distinguishing chemical design, laboratory testing and patient investigation prevents the misleading impression that recognising a cancer-associated molecule automatically yields a medicine ready for use.
From selected cells to selected patients
The 1996 report described inhibition in Bcr-Abl-expressing experimental systems and a comparison involving colonies grown from patient material. A later 2001 paper addressed people rather than isolated cells: its phase 1 study involved83 patients with chronic-phase CML after interferon treatment had failed. Those are different kinds of evidence. The earlier findings supported a rationale for clinical investigation; the trial examined tolerability and responses in a specified patient group. Neither stage should be substituted for the other when explaining the development programme.
Why the endpoints matter
The trial abstract distinguishes blood-related responses from cytogenetic responses, rather than treating all response categories as equivalent. That detail captures an important part of Druker’s research legacy: a plausible target needed measurable tests at several biological scales. His historical work also connects with the earlier chromosome research of Nowell, Hungerford and Rowley, while remaining a later collaborative achievement. A useful biography follows the chain of questions and acknowledges the investigators, trial staff and patients through whom a molecular idea became a body of clinical evidence.
Quick answers
Frequently asked questions about Brian Druker
- What is Brian Druker known for?
- Helping develop and clinically investigate imatinib as a molecularly directed treatment for chronic myeloid leukaemia.
Keep exploring
Lives connected to this story
- Peter Nowell
Connect the later research with the earlier chromosome marker.
- David Hungerford
Read the collaborative observation underlying the Philadelphia chromosome history.
- Dennis Slamon
Compare another programme that moved from a molecular association to a clinical question.
Sources and further reading
Explore the evidence
These references support the biography and offer further reading. Official records, first-person accounts and independent reporting provide different perspectives; image records document attribution and licensing.
- 1. Oregon Health & Science UniversityMeet Dr. Brian Druker
Historical career account: StPaul upbringing, UCSD education, Dana-Farber work and Oregon move in1993. Current2026 organisational titles are omitted from manuscript.
- 2. Lasker FoundationMolecularly targeted treatments for chronic myeloid leukemia
2009 award account: contributions of Lydon, Buchdunger, Zimmermann and Druker; compound development and1996 laboratory comparisons. Not a current-treatment summary.
- 3. Nature MedicineEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Actually read original1996 p561 abstract and opening: selected cellular and tumour-model effects, patient-material colony comparison and research-team affiliations. No unreviewed full-paper figures claimed.
- 4. NEJM / OHSU research repositoryEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
Complete2001 primary abstract reproduced by author’s institution: phase1 dose-escalation,83 chronic-phase patients after interferon failure, separate haematologic/cytogenetic responses and tolerability observations. The NEJM PDF opening independently confirms population and design.
- 5. Tang Prize FoundationBrian J. Druker — Tang Prize laureate
1955 birth metadata; city conflicts with the2019 Swedish Academy award account. Only the common country precision is retained.
